214 related articles for article (PubMed ID: 34543740)
1. Dysregulation of non-coding RNAs mediates cisplatin resistance in hepatocellular carcinoma and therapeutic strategies.
Xu XF; Yang XK; Song Y; Chen BJ; Yu X; Xu T; Chen ZL
Pharmacol Res; 2022 Feb; 176():105906. PubMed ID: 34543740
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Growth-Arrest-Specific Transcript 5 Improved Cisplatin Sensitivity in Hepatocellular Carcinoma Through Sponging miR-222.
Zhao P; Cui X; Zhao L; Liu L; Wang D
DNA Cell Biol; 2020 Apr; 39(4):724-732. PubMed ID: 32213078
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of miR-33a-5p in Hepatocellular Carcinoma: A Possible Mechanism for Chemotherapy Resistance.
Meng W; Tai Y; Zhao H; Fu B; Zhang T; Liu W; Li H; Yang Y; Zhang Q; Feng Y; Chen G
Med Sci Monit; 2017 Mar; 23():1295-1304. PubMed ID: 28291769
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
[TBL] [Abstract][Full Text] [Related]
5. Adipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers.
Kamimura K; Suda T; Fukuhara Y; Okuda S; Watanabe Y; Yokoo T; Osaki A; Waguri N; Ishikawa T; Sato T; Aoyagi Y; Takamura M; Wakai T; Terai S
Sci Rep; 2021 Mar; 11(1):6255. PubMed ID: 33737617
[TBL] [Abstract][Full Text] [Related]
6. Non-coding RNA in drug resistance of hepatocellular carcinoma.
Ding B; Lou W; Xu L; Fan W
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30224380
[TBL] [Abstract][Full Text] [Related]
7. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma.
Wei L; Wang X; Lv L; Liu J; Xing H; Song Y; Xie M; Lei T; Zhang N; Yang M
Mol Cancer; 2019 Oct; 18(1):147. PubMed ID: 31651347
[TBL] [Abstract][Full Text] [Related]
8. miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway.
Shi L; Chen ZG; Wu LL; Zheng JJ; Yang JR; Chen XF; Chen ZQ; Liu CL; Chi SY; Zheng JY; Huang HX; Lin XY; Zheng F
Asian Pac J Cancer Prev; 2014; 15(23):10439-44. PubMed ID: 25556489
[TBL] [Abstract][Full Text] [Related]
9. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity.
Khan MW; Zhao P; Khan A; Raza F; Raza SM; Sarfraz M; Chen Y; Li M; Yang T; Ma X; Xiang G
Int J Nanomedicine; 2019; 14():3753-3771. PubMed ID: 31239661
[No Abstract] [Full Text] [Related]
10. Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.
Zhuang Q; Zhou T; He C; Zhang S; Qiu Y; Luo B; Zhao R; Liu H; Lin Y; Lin Z
J Exp Clin Cancer Res; 2016 Apr; 35():67. PubMed ID: 27074866
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin and farnesol co-encapsulated PLGA nano-particles demonstrate enhanced anti-cancer potential against hepatocellular carcinoma cells in vitro.
Mondal J; Khuda-Bukhsh AR
Mol Biol Rep; 2020 May; 47(5):3615-3628. PubMed ID: 32314187
[TBL] [Abstract][Full Text] [Related]
12. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy.
Hou W; Bonkovsky HL
World J Gastroenterol; 2013 Nov; 19(44):7836-45. PubMed ID: 24307777
[TBL] [Abstract][Full Text] [Related]
13. Modulation of mitochondrial permeability transition pore affects multidrug resistance in human hepatocellular carcinoma cells.
Ling X; Zhou Y; Li SW; Yan B; Wen L
Int J Biol Sci; 2010 Dec; 6(7):773-83. PubMed ID: 21152118
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk between m6A modification and non-coding RNAs in HCC.
Qiu Z; Yuan X; Wang X; Liu S
Cell Signal; 2024 May; 117():111076. PubMed ID: 38309550
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
16. Recent progress in the immunotherapy of hepatocellular carcinoma: Non-coding RNA-based immunotherapy may improve the outcome.
Afra F; Mahboobipour AA; Salehi Farid A; Ala M
Biomed Pharmacother; 2023 Sep; 165():115104. PubMed ID: 37393866
[TBL] [Abstract][Full Text] [Related]
17. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
Qin J; Luo M; Qian H; Chen W
Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of JNK/c-Jun-ATF2 Overcomes Cisplatin Resistance in Liver Cancer through down-Regulating Galectin-1.
Yang F; Li M; Xu D; Jiang Z; Jiang H; Xiao Y; Mei C; Yang M; Chen C; Zhou B; He B; Shan H; Pang P; Li D
Int J Biol Sci; 2023; 19(8):2366-2381. PubMed ID: 37215991
[TBL] [Abstract][Full Text] [Related]
19. TAZ-regulated expression of IL-8 is involved in chemoresistance of hepatocellular carcinoma cells.
Zhang H; Yu QL; Meng L; Huang H; Liu H; Zhang N; Liu N; Yang J; Zhang YZ; Huang Q
Arch Biochem Biophys; 2020 Oct; 693():108571. PubMed ID: 32898567
[TBL] [Abstract][Full Text] [Related]
20. The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma.
Geng W; Ng KT; Sun CK; Yau WL; Liu XB; Cheng Q; Poon RT; Lo CM; Man K; Fan ST
PLoS One; 2011; 6(11):e27362. PubMed ID: 22096562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
